Literature DB >> 20730417

Does agomelatine block 5-HT2C receptors in humans?

Ann L Sharpley, Nancy B Rawlings, Susannah Brain, Sarah F B McTavish, Philip J Cowen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20730417     DOI： 10.1007/s00213-010-1993-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  11 in total

1.  Increased slow wave sleep with 5-HT2 receptor antagonists: detection by ambulatory EEG recording and automatic sleep stage analysis.

Authors:  R A Solomon; A L Sharpley; P J Cowen
Journal:  J Psychopharmacol       Date:  1989-01       Impact factor: 4.153

2.  Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo.

Authors:  A L Sharpley; C M Vassallo; P J Cowen
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

3.  Low dose melatonin improves sleep in healthy middle-aged subjects.

Authors:  M E Attenburrow; P J Cowen; A L Sharpley
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

4.  The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers.

Authors:  Selcuk Aslan; Erdal Isik; Behcet Cosar
Journal:  Sleep       Date:  2002-09-15       Impact factor: 5.849

Review 5.  Effect of pharmacologic treatments on the sleep of depressed patients.

Authors:  A L Sharpley; P J Cowen
Journal:  Biol Psychiatry       Date:  1995-01-15       Impact factor: 13.382

6.  Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects.

Authors:  J P Seibyl; J H Krystal; L H Price; S W Woods; C D'Amico; G R Heninger; D S Charney
Journal:  Psychiatry Res       Date:  1991-09       Impact factor: 3.222

7.  Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

Authors:  Rachel Leproult; Anne Van Onderbergen; Mireille L'hermite-Balériaux; Eve Van Cauter; Georges Copinschi
Journal:  Clin Endocrinol (Oxf)       Date:  2005-09       Impact factor: 3.478

Review 8.  Agomelatine treatment of major depressive disorder.

Authors:  Christian R Dolder; Michael Nelson; Morgan Snider
Journal:  Ann Pharmacother       Date:  2008-11-25       Impact factor: 3.154

9.  The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.

Authors:  M J Millan; A Gobert; F Lejeune; A Dekeyne; A Newman-Tancredi; V Pasteau; J-M Rivet; D Cussac
Journal:  J Pharmacol Exp Ther       Date:  2003-05-15       Impact factor: 4.030

10.  Major depressive disorder, sleep EEG and agomelatine: an open-label study.

Authors:  Maria-Antonia Quera Salva; Bernard Vanier; Judith Laredo; Sarah Hartley; Florian Chapotot; Catherine Moulin; Frédéric Lofaso; Christian Guilleminault
Journal:  Int J Neuropsychopharmacol       Date:  2007-05-04       Impact factor: 5.176
View more
  6 in total

1.  The effect of agomelatine on 5HT(2C) receptors in humans: a clinically relevant mechanism?

Authors:  Trevor R Norman
Journal:  Psychopharmacology (Berl)       Date:  2012-02-15       Impact factor: 4.530

Review 2.  A benefit-risk assessment of agomelatine in the treatment of major depression.

Authors:  Robert H Howland
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

3.  Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study.

Authors:  Michele Fornaro; Michael J McCarthy; Domenico De Berardis; Concetta De Pasquale; Massimo Tabaton; Matteo Martino; Salvatore Colicchio; Carlo Ignazio Cattaneo; Emanuela D'Angelo; Pantaleo Fornaro
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-15       Impact factor: 2.570

4.  Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?

Authors:  Michele Fornaro; Fabio Bandini; Luca Cestari; Christian Cordano; Carla Ogliastro; Claudio Albano; Domenico De Berardis; Matteo Martino; Andrea Escelsior; Giulio Rocchi; Pantaleo Fornaro; Concetta De Pasquale
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-20       Impact factor: 2.570

5.  Effects of typhoid vaccine on inflammation and sleep in healthy participants: a double-blind, placebo-controlled, crossover study.

Authors:  Ann L Sharpley; Charlotte M Cooper; Clare Williams; Beata R Godlewska; Philip J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2016-08-09       Impact factor: 4.530

Review 6.  The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.

Authors:  Domenico De Berardis; Stefano Marini; Michele Fornaro; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Alessandro Valchera; Giampaolo Perna; Maria-Antonia Quera-Salva; Giovanni Martinotti; Massimo di Giannantonio
Journal:  Int J Mol Sci       Date:  2013-06-13       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.